Targeted radionuclide therapy for patients with central nervous system metastasis: Overlooked potential?
Neuro-Oncology · 09.12.2024 · 26 (Supplement_9) · S229-S241
DOI: 10.1093/neuonc/noae192 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neuro-Oncology, online erschienen am 01.10.2024. Verfasst von Emilie Le Rhun und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Hematology, University Hospital and University of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Brain Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Targeted radionuclide therapy is an emerging therapeutic concept for metastatic cancer that can be considered if a tumor can be delineated by nuclear medicine imaging and also targeted based on the expression of a particular target (thera-nostics). This mode of treatment can also compete with or supplement conventional radiotherapy, for example, if MRI does not fully capture the extent of the disease, including microscopic metastases. Targeted radionuclide therapy for patients with thyroid cancer, with certain somatostatin receptor 2-expressing tumors and with prostate-specific membrane antigen-expressing prostate cancer is approved, and numerous approaches of targeted radionuclide therapy for patients with metastatic cancer are in development (eg, using fibroblast activation protein as a target). Although brain metastases are rare in cancers with approved targeted radionuclide therapies, there is no a priori reason to assume that such treatments would not be effective against brain metastases if the targets are expressed and not shielded by the blood-brain barrier. Here, we discuss the current state of the art and opportunities of targeted radionuclide therapies for patients with brain and leptomeningeal metastases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology and Hematology, University Hospital and University of Zurich, Zurich, Switzerland.
- Department of Nuclear Medicine, Ludwig Maximilians-University of Munich, Munich, Germany.
- Department of Nuclear Medicine, University Hospital and University of Zurich, Zurich, Switzerland.
- Nervous System Medical Oncology Department, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, Bologna, Italy.
- Center for Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Duesseldorf, Germany.
- Institute of Neuroscience and Medicine (INM-3), Research Center Juelich, Juelich, Germany.
ORCID-Profile: Emilie Le Rhun, Nathalie L Albert, Norbert Galldiks, Philipp Karschnia, Tobias Weiss, Matthias Preusser, Michael Weller
Förderung
- NCI NIH HHS
Zitieren
APA
Le Rhun, E., Albert, N. L., Hüllner, M., Franceschi, E., Galldiks, N., Karschnia, P., Minniti, G., Weiss, T., Preusser, M., Ellingson, B. M., & Weller, M. (2024). Targeted radionuclide therapy for patients with central nervous system metastasis: Overlooked potential?. Neuro-Oncology, 26(Supplement_9), S229-S241. https://doi.org/10.1093/neuonc/noae192
Vancouver
Le Rhun E, Albert NL, Hüllner M, Franceschi E, Galldiks N, Karschnia P, et al. Targeted radionuclide therapy for patients with central nervous system metastasis: Overlooked potential?. Neuro-Oncology. 2024;26(Supplement_9):S229-S241. doi:10.1093/neuonc/noae192
BibTeX
@article{LeRhun2024,
author = {Le Rhun, Emilie and Albert, Nathalie L and Hüllner, Martin and Franceschi, Enrico and Galldiks, Norbert and Karschnia, Philipp and Minniti, Giuseppe and Weiss, Tobias and Preusser, Matthias and Ellingson, Benjamin M and Weller, Michael},
title = {Targeted radionuclide therapy for patients with central nervous system metastasis: Overlooked potential?},
journal = {Neuro-Oncology},
year = {2024},
volume = {26},
number = {Supplement_9},
pages = {S229--S241},
doi = {10.1093/neuonc/noae192}
}
EUVIMED